Delphia (USA)’s ALX Oncology ALXO Stock Holding History

Delphia (USA)’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,119	Closed	-$82K	–	288
2022 Q2	$82K	Buy	+10,119	New	+$110K	0.06%	357

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Delphia (USA)'s ALXO Position: Q3 2022 in Review

Delphia (USA) sold out of ALX Oncology (ALXO) in Q3 2022, closing a stake of 10,119 shares — an estimated $82K sold.

Delphia (USA) first reported a position in ALXO in Q2 2022 and held it in 1 quarter. The position peaked at $82K in Q2 2022. 99 funds tracked by Wall St. Rank hold ALXO as of Q3 2022.

Delphia (USA) reported no remaining ALX Oncology position as of Q3 2022 after selling out during the quarter.
Delphia (USA) sold 10,119 ALX Oncology shares in Q3 2022, an estimated $82K.
Delphia (USA) first reported a position in ALX Oncology in Q2 2022 and held it in 1 quarter.
Delphia (USA)'s ALX Oncology position peaked at $82K in Q2 2022.
99 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2022.

Based on Delphia (USA)'s 13F filing for Q3 2022, filed 14 Nov 2022.